Search Results - "Simard, John"

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study by Hickish, Tamas, Dr, Andre, Thierry, MD, Wyrwicz, Lucjan, MD, Saunders, Mark, MBBS, Sarosiek, Tomasz, MD, Kocsis, Judit, MD, Nemecek, Radim, MD, Rogowski, Wojciech, MD, Lesniewski-Kmak, Krzysztof, MD, Petruzelka, Lubos, MD, Apte, Ron N, PhD, Mohanty, Prasant, MBBS, Stecher, Michael, MD, Simard, John, BS, de Gramont, Aimery, MD

“…Summary Background MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients…”
Get full text

Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial by Senti, Gabriela, Prinz Vavricka, Bettina M, Erdmann, Iris, Diaz, Mella I, Markus, Richard, McCormack, Stephen J, Simard, John J, Wüthrich, Brunello, Crameri, Reto, Graf, Nicole, Johansen, Pål, Kündig, Thomas M

“…The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy…”
Get full text

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study by Hong, David S, Prof, Hui, David, MD, Bruera, Eduardo, Prof, Janku, Filip, MD, Naing, Aung, MD, Falchook, Gerald S, MD, Piha-Paul, Sarina, MD, Wheler, Jennifer J, MD, Fu, Siqing, MD, Tsimberidou, Apostolia M, MD, Stecher, Michael, MD, Mohanty, Prasant, MBBS, Simard, John, BSc, Kurzrock, Razelle, Prof

“…Summary Background Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. We…”
Get full text

A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia by Varshney, Avanish K, Kuzmicheva, Galina A, Lin, Jian, Sunley, Kevin M, Bowling, Jr, Rodney A, Kwan, Tzu-Yu, Mays, Heather R, Rambhadran, Anu, Zhang, Yanfeng, Martin, Rebecca L, Cavalier, Michael C, Simard, John, Shivaswamy, Sushma

“…Staphylococcus aureus can cause devastating and life-threatening infections. With the increase in multidrug resistant strains, novel therapies are needed…”
Get full text

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer by Kurzrock, Razelle, Hickish, Tamas, Wyrwicz, Lucjan, Saunders, Mark, Wu, Qian, Stecher, Michael, Mohanty, Prasant, Dinarello, Charles A., Simard, John

“…Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is…”
Get full text

IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19 by Renieris, Georgios, Karakike, Eleni, Gkavogianni, Theologia, Droggiti, Dionysia-Eirini, Stylianakis, Emmanouil, Andriopoulou, Theano, Spanou, Victoria-Marina, Kafousopoulos, Dionyssios, Netea, Mihai G., Eugen-Olsen, Jesper, Simard, John, Giamarellos-Bourboulis, Evangelos J.

“…Abstract Acute respiratory distress syndrome (ARDS) in COVID-19 has been associated with catastrophic inflammation. We present measurements in humans and a new…”
Get full text

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer by Hong, David S., Janku, Filip, Naing, Aung, Falchook, Gerald S., Piha-Paul, Sarina, Wheler, Jennifer J., Fu, Siqing, Tsimberidou, Apostolia M., Stecher, Michael, Mohanty, Prasant, Simard, John, Kurzrock, Razelle

“…Summary Background Advanced non-small cell lung cancer (NSCLC) patients were treated as part of a Phase I dose escalation and expansion study evaluating a true…”
Get full text

Deregulated T Cell Activation and Autoimmunity in Mice Lacking Interleukin- 2 Receptor β by Suzuki, Haruhiko, Kündig, Thomas M., Furlonger, Caren, Wakeham, Andrew, Timms, Emma, Matsuyama, Toshifumi, Schmits, Rudolf, John J. L. Simard, Ohashi, Pamela S., Griesser, Henrik, Taniguchi, Tadatsugu, Paige, Christopher J., Mak, Tak W.

“…In mice lacking the interleukin-2 receptor β chain (IL-2Rβ), T cells were shown to be spontaneously activated, resulting in exhaustive differentiation of B…”
Get full text

Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs by Kündig, Thomas M., Bachmann, Martin F., DiPaolo, Claudio, John J. L. Simard, Battegay, Manuel, Lother, Heinz, Gessner, André, Kühlcke, Klaus, Ohashi, Pamela S., Hengartner, Hans, Zinkernagel, Rolf M.

“…Only so-called "professional" antigen-presenting cells (APCs) of hematopoietic origin are believed capable of inducing T lymphocyte responses. However,…”
Get full text

Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice by Amakawa, Ryuichi, Hakem, Anne, Kundig, Thomas M, Matsuyama, Toshifumi, Simard, John J.L, Timms, Emma, Wakeham, Andrew, Mittruecker, Hans-Willi, Griesser, Henrik, Takimoto, Hiroaki, Schmits, Rudolf, Shahinian, Arda, Ohashi, Pamela S, Penninger, Josef M, Mak, Tak W

“…CD30 is found on Reed–Sternberg cells of Hodgkin's disease and on a variety of non-Hodgkin's lymphoma cells and is up-regulated on cells after Epstein–Barr…”
Get full text

CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity by SCHMITS, R, FILMUS, J, FURLONGER, C, ZAKARIAN, A, SIMARD, J. J. L, OHASHI, P. S, PAIGE, C. J, GUTIERREZ-RAMOS, J. C, MAK, T. W, GERWIN, N, SENALDI, G, KIEFER, F, KUNDIG, T, WAKEHAM, A, SHAHINIAN, A, CATZAVELOS, C, RAK, J

“…CD44 is expressed in various isoforms on numerous cell types and tissues during embryogenesis and in the mature organism. CD44 may also be involved in tumor…”
Get full text

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study by Kanni, Theodora, Argyropoulou, Maria, Spyridopoulos, Themistoklis, Pistiki, Aikaterini, Stecher, Michael, Dinarello, Charles A., Simard, John, Giamarellos-Bourboulis, Evangelos J.

“…Patients with moderate to severe hidradenitis suppurativa failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet…”
Get full text

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain by Gottlieb, Alice, Natsis, Nicola E., Kerdel, Francisco, Forman, Seth, Gonzalez, Edgar, Jimenez, Gilberto, Hernandez, Liliam, Kaffenberger, Jessica, Guido, Giancarlo, Lucas, Kathryn, Montes, Diego, Gold, Michael, Babcock, Chad, Simard, John

“…The objective of this study was to evaluate the safety and efficacy of bermekimab, an IL-1α inhibitor, in the treatment of hidradenitis suppurativa (HS). This…”
Get full text

CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity by Schmits, Rudolf, Filmus, Jorge, Gerwin, Nicole, Senaldi, Giorgio, Kiefer, Friedemann, Kundig, Thomas, Wakeham, Andrew, Shahinian, Arda, Catzavelos, Charles, Rak, Janusz, Furlonger, Caren, Zakarian, Arsen, Simard, John J.L., Ohashi, Pamela S., Paige, Christopher J., Gutierrez-Ramos, Jose C., Mak, Tak W.

“…CD44 is expressed in various isoforms on numerous cell types and tissues during embryogenesis and in the mature organism. CD44 may also be involved in tumor…”
Get full text

Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point by Gong, Jun, Wu, Daniel, Chuang, Jeremy, Tuli, Richard, Simard, John, Hendifar, Andrew

“…This review highlights the evidence supporting symptom control and quality-of-life (QOL) measures as predictors of survival in treatment-refractory metastatic…”
Get full text

Postischemic Administration of IL-1α Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke by Liberale, Luca, Bonetti, Nicole R., Puspitasari, Yustina M., Schwarz, Lena, Akhmedov, Alexander, Montecucco, Fabrizio, Ruschitzka, Frank, Beer, Jürg H., Lüscher, Thomas F., Simard, John, Libby, Peter, Camici, Giovanni G.

Get full text

On the Role of Antigen in Maintaining Cytotoxic T-Cell Memory by Kündig, Thomas M., Bachmann, Martin F., Oehen, Stephan, Hoffmann, Urs W., John J. L. Simard, Kalberer, Christian P., Pircher, Hanspeter, Ohashi, Pamela S., Hengartner, Hans, Zinkernagel, Rolf M.

“…This study evaluated whether T-cell memory reflects increased precursor frequencies of specific long-lived T cells and/or a low-level immune response against…”
Get full text

MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PT026) by Wyrwicz, Lucjan, Saunders, Mark P., Andre, Thierry, Sarosiek, Tomasz, Nemecek, Radim, Rogowski, Wojciech, Leśniewski-Kmak, Krzysztof, Fisher, George A., Stecher, Michael, Mohanty, Prasant, Simard, John, Hickish, Tamas

“…Abstract only 3530 Background: Refractory metastatic colorectal cancer (mCRC) patients derive minimal benefit from further exposure to toxic agents. MABp1 is…”
Get full text

Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1) by Kurzrock, Razelle, Hickish, Tamas, Wyrwicz, Lucjan, André, Thierry, Sarosiek, Tomasz, Kocsis, Judit, Nemecek, Radim, Wu, Qian, Mohanty, Prasant, Stecher, Mike, Simard, John, Dinarello, Charles

Get full text

MABp1, a first-in-class true human antibody targeting interleukin-1[alpha] in refractory cancers: an open-label, phase 1 dose-escalation and expansion study by Hong, David S, Hui, David, Bruera, Eduardo, Janku, Filip, Naing, Aung, Falchook, Gerald S, Piha-Paul, Sarina, Wheler, Jennifer J, Fu, Siqing, Tsimberidou, Apostolia M, Stecher, Michael, Mohanty, Prasant, Simard, John, Kurzrock, Razelle

“…Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. We used a…”
Get full text